4//SEC Filing
Gupta Rishi 4
Accession 0000947871-23-000778
CIK 0001764974other
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 4:40 PM ET
Size
17.5 KB
Accession
0000947871-23-000778
Insider Transaction Report
Form 4
Gupta Rishi
Director
Transactions
- Conversion
Series C Preferred Stock
2023-07-20−266,240→ 0 total(indirect: See Footnotes)→ Common Stock (266,240 underlying) - Conversion
Common Stock
2023-07-20+2,682,599→ 2,682,599 total(indirect: See Footnote) - Purchase
Common Stock
2023-07-20$12.00/sh+416,666$4,999,992→ 3,099,265 total(indirect: See Footnote) - Conversion
Series B-2 Preferred Stock
2023-07-20−1,249,829→ 0 total(indirect: See Footnotes)→ Common Stock (1,249,829 underlying) - Conversion
Series B-1 Preferred Stock
2023-07-20−937,372→ 0 total(indirect: See Footnotes)→ Common Stock (937,372 underlying) - Conversion
Series D Preferred Stock
2023-07-20−229,158→ 0 total(indirect: See Footnotes)→ Common Stock (229,158 underlying)
Footnotes (3)
- [F1]Each share of Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock automatically converted into shares of the Issuer's common stock on a one-to-one basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- [F2]These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
- [F3]Each of the Reporting Person, OrbiMed Advisors and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Turnstone Biologics Corp.
CIK 0001764974
Entity typeother
Related Parties
1- filerCIK 0001537370
Filing Metadata
- Form type
- 4
- Filed
- Jul 23, 8:00 PM ET
- Accepted
- Jul 24, 4:40 PM ET
- Size
- 17.5 KB